Haima

Haima is a prescription oral medication that contains the antifibrinolytic agent tranexamic acid. Although the specific strength is not disclosed, the product is marketed in the European Union as a hemostatic agent that works by inhibiting the conversion of plasminogen to plasmin, thereby reducing fibrinolysis and helping to stabilize blood clots. It is classified under ATC code B02AA02 and is used under medical supervision for patients.

Haima is indicated for the management of bleeding in several clinical situations where reduction of fibrinolysis is desired.

- Treatment of heavy menstrual bleeding (menorrhagia) in women of reproductive age. - Control of bleeding associated with trauma, including blunt or penetrating injuries. - Prevention of excessive blood loss during surgical procedures such as orthopedic, cardiac, or dental surgery. - Management of bleeding in patients with hereditary hemorrhagic telangiectasia or other rare bleeding disorders. - Adjunct therapy for patients receiving anticoagulant reversal when rapid hemostasis is required.

Side effects reported with oral tranexamic acid such as Haima vary in frequency and severity; most are mild, while a few may require medical attention.

Common: - Nausea or upset stomach. - Diarrhea or loose stools. - Headache or dizziness. - Nasal congestion or mild sinus discomfort. - Mild fatigue or feeling of weakness. - Transient visual disturbances such as blurred vision.

Serious: - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. - Severe allergic reactions, including rash, itching, swelling, or anaphylaxis. - Kidney impairment or reduced renal function, especially in patients with pre‑existing renal disease.

When prescribing Haima, clinicians consider several precautionary measures to minimize risk and ensure safe use in appropriate patient populations.

- Assess history of thromboembolic disease before initiating therapy. - Use caution in patients with renal impairment; dose adjustment may be required. - Evaluate for known hypersensitivity to tranexamic acid or any excipients. - Monitor for signs of clot formation during prolonged treatment. - Avoid use in individuals with active intravascular clotting or recent myocardial infarction. - Consider pregnancy status, as safety data are limited. - Review concomitant use of hormonal contraceptives that may increase clot risk.

Tranexamic acid may interact with other medicines, altering its effectiveness or increasing the risk of adverse events; understanding these interactions helps guide safe co‑administration.

Avoid: - Combined use with other antifibrinolytic agents, as this may excessively suppress fibrinolysis. - Concomitant administration of hormonal estrogen therapy or selective estrogen receptor modulators in patients at high risk for thrombosis.

Use with caution: - Concurrent anticoagulants (e.g., warfarin, direct oral anticoagulants) because tranexamic acid can counteract their effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase bleeding risk if clot stabilization is insufficient. - Oral contraceptives, especially combined estrogen‑progestin pills, due to additive clot‑promoting potential. - Certain antibiotics such as erythromycin that can affect plasma levels of tranexamic acid.